IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

NCT ID: NCT03981900

Last Updated: 2024-10-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

314 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-04

Study Completion Date

2023-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available.

Therefore, the primary objective of the DeFacTo study will be to identify the factors predictive of Tofacitinib drug survival in patients with RA.

As secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational, open-label, prospective, multi-centre, national study designed to evaluate the factors predictive of Tofacitinib's survival in patients with rheumatoid arthritis

If catastrophisation is described as a distortion of the perception of pain involving a both emotional and cognitive component, pushing the patient to see only the worst, coping involves adaptive strategies by which the patient attempts to find solutions in order to better cope with his/her disease. It has been demonstrated that such behavioural strategies can influence directly or indirectly the intensity of symptoms in patients suffering from chronic disease.

Therefore, as secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.

The duration of this study will be approximately 48 months including a 24-month recruitment period and a 24-month patient follow-up period.

Patients will be followed prospectively and follow-up visits will be conducted after the initial consultations. No visit or additional test is required by the protocol, since the study is observational

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatoid arthritis

All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib

Tofacitinib

Intervention Type DRUG

5 mg BID, oral administrtaion

Tofacitinib

Intervention Type DRUG

tablet form 11mg once daily oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tofacitinib

5 mg BID, oral administrtaion

Intervention Type DRUG

Tofacitinib

tablet form 11mg once daily oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xeljanz Xeljanz

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient 18 years of age or older
* Patient in whom the diagnosis of moderate to severe active rheumatoid arthritis has been confirmed by a rheumatologist
* Patient for whom the rheumatologist decides to initiate treatment with Tofacitinib
* Patient informed of the study

Exclusion Criteria

* Patient participating in a randomised clinical trial.
* Patient presenting with a contraindication to prescription of Tofacitinib
* Patients who are investigational site staff members or patients who are Pfizer employees directly involved in the conduct of the trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier D'arras

Arras, , France

Site Status

Hopital Robert Ballanger

Aulnay-sous-Bois, , France

Site Status

Cabinet Medical

Aurillac, , France

Site Status

Centre Hospitalier D Auxerre

Auxerre, , France

Site Status

Institut Calot Helio Marin

Berck, , France

Site Status

hopital Avicenne

Bobigny, , France

Site Status

Centre Hospitalier de Fleyriat

Bourg-en-Bresse, , France

Site Status

Hopital Jacques Cœur

Bourges, , France

Site Status

Cabinet Medical

Brest, , France

Site Status

Cabinet Medical

Brive-la-Gaillarde, , France

Site Status

Cabinet Medical

Bruges, , France

Site Status

Centre Hospitalier Jean Rougier

Cahors, , France

Site Status

Infirmerie Protestante de Lyon

Caluire-et-Cuire, , France

Site Status

Hopital Pierre Nouveau

Cannes, , France

Site Status

Centre Hospitalier de Carcassonne

Carcassonne, , France

Site Status

Hopital Gabriel Montpied

Clermont-Ferrand, , France

Site Status

Centre Hospitalier de Compiegne

Compiègne, , France

Site Status

Hopital Henri Mondor

Créteil, , France

Site Status

Hopital Victor Jousselin

Dreux, , France

Site Status

Centre Hospitalier des Deux Vallees Juvisy

Juvisy-sur-Orge, , France

Site Status

Cabinet Medical

La Battie Vieille, , France

Site Status

Cabinet Medical

La Moutonne, , France

Site Status

Centre Hospitalier Departemental Vendee Les Oudairies

La Roche-sur-Yon, , France

Site Status

Hopital Suburbain Du Bouscat

Le Bouscat, , France

Site Status

Hopital Suburbain

Le Bouscat, , France

Site Status

Centre Hospitalier Universitaire de Lille - Hopital B Roger Salengro

Lille, , France

Site Status

Hopital B Roger Salengro-chu De Lille

Lille, , France

Site Status

Hopital Dupuytren

Limoges, , France

Site Status

Cabinet Medical

Limoges, , France

Site Status

Clinique de La Sauvegarde / Cabinet Le Trait D Union

Lyon, , France

Site Status

Clinique de la Sauvegarde

Lyon, , France

Site Status

Clinique du Pont de Chaume

Montauban, , France

Site Status

Centre Hospitalier de Montauban

Montauban, , France

Site Status

Centre Hospitalier Montceau Les Mines-Hopital Jean Bouveri

Montceau-les-Mines, , France

Site Status

Hopital Jacques Monod

Montivilliers, , France

Site Status

Cabinet Medical

Montpellier, , France

Site Status

Cabinet Medical Saint Roch

Montpellier, , France

Site Status

Clinique Beau Soleil

Montpellier, , France

Site Status

Hopital Lapeyronie

Montpellier, , France

Site Status

Hopital Caremeau

Nîmes, , France

Site Status

Centre Hospitalier Orleans-Hopital La Source

Orléans, , France

Site Status

Cabinet Medical

Paris, , France

Site Status

Centre Hospitalier Pitie Salpetriere

Paris, , France

Site Status

Hopital Cochin

Paris, , France

Site Status

Hopital Bichat Claude Bernard

Paris, , France

Site Status

Centre Hospitalier de Perigueux

Périgueux, , France

Site Status

Hospices Civils de Lyon - Hopital Lyon Sud- Hematologie

Pierre-Bénite, , France

Site Status

Cabinet Medical

Poitiers, , France

Site Status

Centre Hospitalier La Miletrie

Poitiers, , France

Site Status

Centre Hospitalier Annecy Genevois Site Annecy

Pringy, , France

Site Status

Hopital Charles Nicolle

Rouen, , France

Site Status

Cabinet Medical

Saint-Lô, , France

Site Status

Hopital Inter-armees Begin

Saint-Mandé, , France

Site Status

Centre Hospitalier Universitaire Saint Pierre

Saint-Pierre, , France

Site Status

Centre Hospitalier Universitaire Saint Etienne Hopital Nord

Saint-Priest-en-Jarez, , France

Site Status

Hopital Nord

Saint-Priest-en-Jarez, , France

Site Status

Centre Hospitalier de Bigorre Site La Gespe

Tarbes, , France

Site Status

Clinique Medipole Garonne

Toulouse, , France

Site Status

Hopital Purpan

Toulouse, , France

Site Status

Cabinet Medical

Toulouse, , France

Site Status

Cabinet de Rhumatologie

Tours, , France

Site Status

Cabinet Medical

Tours, , France

Site Status

Hopital des Hauts Clos

Troyes, , France

Site Status

Cabinet Medical

Valenciennes, , France

Site Status

Hopital Psv

Villeneuve-sur-Lot, , France

Site Status

Cabinet Medical

Vincennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=A3921313

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DeFacTo

Identifier Type: OTHER

Identifier Source: secondary_id

A3921313

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.